Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL614102 Target Snapshot

PC-9 · CELL-LINE · Homo sapiens

Back to Search Search this target Browse approvals Evidence Card
799Compounds
531Assays
19Approved Drugs
835.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-14

Confirm a stable target identifier before relying on this context across project surfaces.

Review focus
Open DB context pending

Confirm a stable target identifier before relying on this context across project surfaces.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-14
Open source guide
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats PC-9 as ChEMBL target CHEMBL614102. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
PC-9
CELL-LINE · Homo sapiens
As of 2026-09-14
ChEMBL target ID
CHEMBL614102
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether PC-9 still has a stable protein naming contract across sources.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need the strongest disease program and evidence level in one place.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred NamePC-9
Target TypeCELL-LINE
OrganismHomo sapiens
ChEMBL ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelPC-9
UniProt AccessionN/A

PC-9

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as PC-9.

Review namePC-9
OrganismHomo sapiens
Clinical Profile

Clinical Phase Distribution

19
Approved
5
Phase III
3
Phase II
Assay Mix

Activity Type Distribution

IC50747.0
EC5088.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL3353410 10.96 IC50 0.011 Approved
CHEMBL5593632 10.96 IC50 0.011 Preclinical
CHEMBL5594833 10.74 IC50 0.018 Preclinical
CHEMBL5590430 10.72 IC50 0.019 Preclinical
CHEMBL5284780 10.7 IC50 0.02 Preclinical
CHEMBL5593035 10.68 IC50 0.021 Preclinical
CHEMBL5592071 10.52 IC50 0.03 Preclinical
CHEMBL5584148 10.51 IC50 0.031 Preclinical
CHEMBL5594458 10.48 IC50 0.033 Preclinical
CHEMBL5593053 10.41 IC50 0.039 Preclinical
Distribution

pChEMBL Value Distribution

136
5.0
80
5.5
76
6.0
65
6.5
58
7.0
43
7.5
24
8.0
22
8.5
13
9.0
18
9.5
pChEMBL
Approved Drugs

Approved Drugs

DACOMITINIB ANHYDROUS
CHEMBL2110732
Approved 2018
Properties Compare Identifier
BRIGATINIB
CHEMBL3545311
Approved 2017
Properties Compare Identifier
NERATINIB
CHEMBL180022
Approved 2017
Properties Compare Identifier
OSIMERTINIB
CHEMBL3353410
Approved 2015
Properties Compare Identifier
AFATINIB
CHEMBL1173655
Approved 2013
Properties Compare Identifier
ERLOTINIB
CHEMBL553
Approved 2004
Properties Compare Identifier
GEFITINIB
CHEMBL939
Approved 2003
Properties Compare Identifier
PACLITAXEL
CHEMBL428647
Approved 1992
Properties Compare Identifier
DOXORUBICIN
CHEMBL53463
Approved 1974
Properties Compare Identifier
Assay Landscape

Assay Landscape

538
Total Assays
554
Tested Compounds
3
Assay Types
Functional — 529 assays, 554 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 470 554 6.4
organism-based format 59 0 —
Toxicity — 5 assays, 0 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 5 0 —
ADME — 4 assays, 1 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 4 1 5.4

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine